Pharmala Biotech Holdings Inc. (CSE:MDMA)

Canada flag Canada · Delayed Price · Currency is CAD
0.0950
-0.0100 (-9.52%)
At close: Feb 27, 2026
-48.65%
Market Cap 10.35M
Revenue (ttm) 754.64K
Net Income (ttm) -2.11M
Shares Out 108.93M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,500
Average Volume 50,875
Open 0.1050
Previous Close 0.1050
Day's Range 0.0950 - 0.1050
52-Week Range 0.0850 - 0.2000
Beta 0.77
RSI 42.64
Earnings Date Apr 29, 2026

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Nicholas Kadysh
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MDMA
Full Company Profile

Financial Performance

In fiscal year 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.

Financial Statements

News

There is no news available yet.